Investing.com Calliditas Interim Report January to June 2024

Stockholm, August 13, 2024 /PRNewswire/—— Kaliditas Therapeutics, Inc. (Nasdaq: CALT) (STO: CALTX) :

April to June 2024 (in comparison with April June 2023)

• Web gross sales reached SEK 559.8 millionthe place Tapeyo ^® Web gross sales reached SEK 493.4 millionas of three months June 30, 2024. As of three months June 30, 2023web gross sales amounted to SEK 269.4 millionof which TARPEYO’s web gross sales amounted to SEK 259.2 million.
• Working losses amounted to SEK 31.5 million and SEK 75.2 million three months finish June 30, 2024and 2023. Nonetheless, costs associated to the Asahi Kasei Provide and costs associated to Social Safety Contributions to the Incentive Plan had been included within the second quarter, totaling SEK 101.7 million. After deducting these bills, adjusted working revenue¹ Equal to SEK 70.2 million three months finish June 30, 2024.
• Loss per share earlier than and after dilution is Swedish Krona 0.88 and SEK 1.71 three months finish June 30, 2024and 2023.
• The money quantity is SEK 797.3 million and SEK 866.2 million As of June 30, 2024and 2023.

January to June 2024 (With January to June 2023)

• Web gross sales reached SEK 855.3 millionthe place Tapeyo ^® Web gross sales reached SEK 771.6 millionas of six months June 30, 2024. as of six months June 30, 2023web gross sales amounted to SEK 460.7 millionof which TARPEYO’s web gross sales amounted to SEK 444.9 million.
• Working losses amounted to SEK 235.3 million and SEK 255.2 million as of six months June 30, 2024and 2023. Nonetheless, costs associated to the Asahi Kasei Provide and costs associated to Social Safety Contributions to the Incentive Plan had been included within the second quarter, totaling SEK 101.7 million. Adjusted working loss excluding these bills¹ Equal to SEK 133.6 million as of six months June 30, 2024.
• Loss per share earlier than and after dilution is SEK 5.47 and 5.21 Swedish Krona as of six months June 30, 2024and 2023.

Key takeaways from Season 2 2024

• In April, Calliditas introduced optimistic information from Nefecon’s open-label Section 3 growth trial.
• In Might, Calliditas introduced optimistic outcomes from a Section 2 trial of setanaxib in head and neck most cancers.
• In Might, Calliditas companion Everest Medicines introduced that Nefecon China.
• Might, crafty companion herd Acquired optimistic opinion from CHMP recommending full approval of Kinpeygo ^® Used within the EU to deal with IgA nephropathy.
• In June, Calliditas introduced that the US Patent and Trademark Workplace (USPTO) had granted a brand new patent to setanaxib for the therapy of most cancers. The patent will expire in 2039.

Essential issues after the reporting interval

• July, crafty companion herd Acquired European Fee Determined to totally approve Kinpeygo ® for the therapy of IgA nephropathy.
• In July, Calliditas introduced topline Section 2b information from TRANSFORM in main biliary cholangitis.

Asahi Kasei Low cost

• Asahi Kasei Company introduced Might 28, 2024public money provide to accumulate all shares of Calliditas 208 SEK Money per share (416 Swedish Krona Every ADS is payable in money). The provide represents a premium of 83% in comparison with the closing worth of Nasdaq shares in Stockholm Might 27, 2024.
• The acceptance interval for the provide begins on July 18, 2024and expires on August 30, 2024topic to any extensions.

Waiting for 2024: Up to date

Calliditas expects continued income progress: Complete web gross sales (together with milestones) for the Nefecon franchise are anticipated to be US$165-185 million to the top of the yr December 31, 2024.

Investor introduction

Right now, August thirteenth 2.30pm CET

Webcast hyperlink:
https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024

To take part by way of convention name, please register by way of the hyperlink beneath:
https://convention.financialhearings.com/teleconference/?id=50049712

After registering, you’ll obtain a cellphone quantity and assembly ID to log into the convention name. There can be no Q&A session following the presentation.

For extra info please contact:
àsa Hillsten, Head of Investor Relations and Sustainability at Calliditas
Telephone: +46 76 403 35 43, E-mail: asa.hillsten@calliditas.com

The data within the report is info that Calliditas is obliged to reveal underneath the EU Market Abuse Regulation and the Securities Markets Act. This info has been despatched to the publication by means of the company of the above contact particular person, August 13, 2024exist 7:00 AM CET.

¹Administration makes use of and presents IFRS outcomes and the non-IFRS measure of adjusted working revenue to judge and talk its efficiency. Whereas non-IFRS measures shouldn’t be thought-about an alternative choice to IFRS measures, administration believes that non-IFRS measures are helpful in additional understanding Calliditas’ present outcomes, efficiency tendencies and monetary situation. Adjusted working revenue is outlined as IFRS working revenue (loss) much less reserves for social safety contributions for incentive plans and advisory charges for Asahi Kasei’s public providing. A reconciliation of Adjusted Working Revenue to Working Revenue (Loss), essentially the most instantly comparable IFRS measure, is about out on web page 31 of the hooked up report.

About sensible

Expert therapy strategies is a biopharmaceutical firm headquartered in Stockholm, Swedencentered on figuring out, creating and commercializing novel therapies for orphan indications with important unmet medical want. Calliditas’ atypical shares are listed on Nasdaq Stockholm (ticker image: CALTX) and its American depositary shares are listed on the Nasdaq World Choose Market (ticker image: CALT). Please go to Calliditas.com to study extra.

forward-looking statements

This press launch incorporates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995, as amended, together with, with out limitation, statements concerning Calliditas’ technique, enterprise plans, income and different monetary projections and priorities. Phrases reminiscent of “might”, “will”, “might”, “would”, “ought to”, “count on”, “plan”, “anticipate”, “intend”, “consider”, “estimate”, “predict” and many others. The phrases “mission,” “potential,” “proceed,” “purpose” and comparable expressions are meant to establish forward-looking statements, though not all forward-looking statements comprise these figuring out phrases. Any forward-looking statements on this press launch are primarily based on administration’s present expectations and beliefs and are topic to plenty of dangers, uncertainties and essential elements that might trigger precise occasions or outcomes to vary from these expressed or implied in any forward-looking assertion. The content material of this launch differs materially from statements contained on this press launch, together with, with out limitation, statements concerning Calliditas’ enterprise, operations, commercialization of TARPEYO, Kinpeygo and Nefecon, medical trials, provide chain, methods, aims and anticipated growth timelines and potential approvals. , any statements associated to competitors from different biopharmaceutical firms, income and product gross sales forecasts or projections, together with 2024 whole web gross sales steering and money runway, all statements concerning Asahi Kasei Company’s public choices, profitability and in stories filed by Calliditas The opposite dangers recognized within the part titled “Threat Elements” are associated to Securities and Change Fee. Kaliditas cautions you to not place undue reliance on any forward-looking statements, which communicate solely as of the date hereof. Calliditas undertakes no obligation to publicly replace or revise any such assertion to replicate any adjustments in expectations or occasions, situations or circumstances on which any such assertion relies or which will have an effect on the likelihood that precise outcomes will differ from these acknowledged. sexual statements. Any forward-looking statements contained on this press launch symbolize Calliditas’s views solely as of the date of this press launch and shouldn’t be relied upon as representing its views as of any subsequent date.

This info is delivered to you by Cision http://information.cision.com

https://information.cision.com/calliditas-therapeutics/r/calliditas-interim-report-january-to-june-2024,c4023451

The next recordsdata can be found for obtain: